10-Q quarterly report · filed Oct 27, 2026

Beta Bionics, Inc. (BBNX) Q3 2026 10-Q Quarterly Report

Short answer

Beta Bionics, Inc. (BBNX) filed its Q3 2026 10-Q quarterly report on Oct 27, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $36M (up 30.3% year over year) with net income of −$24M.

Q3 2026 key financials · XBRL

Revenue
$36M
+30.3% YoY · +10.9% QoQ
Net income
−$24M
−71.4% YoY · −4.1% QoQ
Operating margin
-74.9%
Gross margin
57.3%
EPS (diluted)
−$0.52
−79.3% YoY · +1.9% QoQ

Source: XBRL data from the Beta Bionics, Inc. (BBNX) Q3 2026 10-Q on SEC EDGAR. USD.

Beta Bionics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $35.5M, up from $27.3M YoY, driven by higher single-use product volumes and new patient starts
  • Gross margin 57.3% vs 55.5% YoY, while net loss widened to $24.4M from $14.2M
  • Single-use products strongest line, 68% of sales vs 47%; PBP sales 38% vs 23% YoY
  • Cash, equivalents and investments $373.6M; operating cash used $50.7M, follow-on offering provided $161.8M
  • Mint launch targeted Q1 2027; FDA Warning Letter remediation, inflation, tariffs and supply risks remain headwinds

Risk Factors

  • Mint FDA clearance in September 2026 created commercialization risk, with U.S. launch targeted by end of first quarter 2027
  • 3D Intelligence 510(k) withdrawal in October 2026 delayed next-generation iLet 3D and Mint 3D plans
  • FDA Warning Letter cited Quality Management System, Medical Device Reporting, and Correction and Removals deficiencies
  • September 2026 securities class action alleges federal securities-law violations concerning iLet safety, efficacy, and commercial success
  • September 2026 follow-on offering raised net proceeds of approximately $161.3 million, but additional capital may still be required

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Beta Bionics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.